Neimeth’s earnings rebound resets a volatile five-year cycle

After a turbulent half-decade marked by sharp swings between profit and loss, Neimeth International Pharmaceuticals Plc closed 2025 with its strongest earnings recovery in years, resetting the company’s financial narrative and reframing investor expectations around sustainability rather than mere turnaround.

A review of Neimeth’s five-year financial trajectory shows a business that entered the decade on a relatively stable footing, slipped into prolonged earnings stress, and only recently clawed its way back to profitability.

In the 2021 financial year, Neimeth reported a profit after tax of N270.6 million on revenue of N3.05 billion, supported by moderate operating margins and manageable finance costs. That year marked the high point of the company’s pre-disruption earnings profile, before cost pressures, currency volatility and balance-sheet strain began to weigh more heavily on performance.

By 2023, the picture had deteriorated sharply. Revenue declined to N2.21 billion, while foreign exchange losses surged, pushing the company to a loss after tax of N2.87 billion. Operating performance was overwhelmed by currency-related charges and rising finance costs, eroding equity and deepening accumulated losses. Net assets stood at N1.47 billion at the end of 2023, reflecting the cumulative impact of consecutive loss years.

The 2024 financial year extended this stress phase. Neimeth remained in the red, reporting a loss after tax of N885.3 million, underscoring how difficult it had become for pharmaceutical manufacturers to convert revenue growth into bottom-line resilience amid FX exposure, rising input costs, and expensive debt.

For the year ended December 31, 2025, Neimeth returned decisively to profitability, posting a profit after tax of N982.1 million. Revenue rose 64 percent year on year to N7.37 billion, while operating profit expanded to N2.71 billion. The earnings rebound was driven by a combination of higher sales volumes, price adjustments, and a sharp reduction in foreign exchange losses that had previously distorted results.

Managing director and chief executive Valentine Okelu described the shift as structural rather than cyclical. “We reversed a negative bottom line from 2024 with an operating profit of N2.71 billion,” he said at the company’s 2026 strategy parley. “This represents an absolute profit improvement of over N1.6 billion compared to the previous cycle.”

Despite the profit recovery, cash flow remains the unresolved tension in Neimeth’s earnings story. Operating cash flow for 2025 was negative N3.4 billion, largely due to a more than doubling of inventories to N3.89 billion. For investors, this highlights a familiar pharmaceutical trade-off: revenue growth and market expansion often come at the cost of working-capital intensity.

Finance costs also remain elevated. Interest expense of N1.22 billion absorbed a meaningful share of operating profit, reflecting the legacy of high-cost borrowing accumulated during the loss years. Management has responded by restructuring debt and converting foreign-denominated loans into naira to limit further volatility.

The market, however, has already moved ahead of the fundamentals. As of February 5, 2026, Neimeth’s share price had risen to N12.20 from N5.80 at the start of the year, delivering a 91 percent year-to-date gain and lifting market capitalisation to about N47.4 billion. At that valuation, investors are pricing in not just a rebound year, but the expectation that 2025 marks the start of a more durable earnings phase.

Whether Neimeth can translate its profit recovery into consistent cash generation will determine if this rally proves prescient or premature. For now, the five-year trend shows a company that has survived a deep earnings trough and re-emerged, but one still being judged on execution rather than promise.